Actively Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2025-09-12
414
Participants Needed
20
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
CONDITIONS
Official Title
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before starting the study
- Able and willing to comply with study visits and procedures
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Previously treated by standard therapy or untreated for metastatic disease
- Adequate organ and bone marrow function
- At least one measurable extracranial tumor lesion
- Available adequate archival tissue from prior biopsy
You will not qualify if you...
- Prior therapy targeting HER3 including antibodies, ADCs, or CAR-T therapies
- Intolerance to topoisomerase I inhibitors or ADCs containing them
- Participation in other interventional clinical studies or insufficient washout from prior anti-tumor therapy
- Major surgery within 4 weeks before first dose or planned major surgery during study
- Previous allogeneic bone marrow or solid organ transplant
- Systemic steroids or immunosuppressive treatment within 2 weeks before first dose
- Live vaccine within 4 weeks before first dose or planned during study
- Presence of meningeal metastasis or cancerous meningitis
- Brain metastasis or spinal cord compression
- Uncontrolled or significant cardiovascular disease
- Significant pulmonary disorders
- Diagnosis of Gilbert syndrome
- Uncontrolled effusion requiring repeated drainage
- Recent gastrointestinal perforation, fistula, active ulcers or other serious GI diseases
- Serious infection before first dose
- Known HIV infection
- Active hepatitis B or C infection
- History of other primary malignancies within 5 years
- Unresolved toxicity from previous anti-tumor therapy
- History of severe hypersensitivity to study drugs or monoclonal antibodies
- Pregnant or lactating women
- Any medical, mental, or social condition interfering with consent, participation, or result interpretation according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)
Hefei, Anhui, China, 230001
Not Yet Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Not Yet Recruiting
3
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510555
Not Yet Recruiting
4
Meizhou People's Hospital（Huangtang Hospital）Meizhou Academy of Medical Sciences
Meizhou, Guangdong, China, 514031
Not Yet Recruiting
5
Ghang xi Medical University Cancer Hospital
Nanning, Guangxi, China, 530028
Not Yet Recruiting
6
Affiliated Hospital Of Hebei University
Baoding, Hebei, China, 71051
Not Yet Recruiting
7
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081
Not Yet Recruiting
8
Anyang Cancer Hospital
Anyang, Henan, China, 455100
Not Yet Recruiting
9
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China, 471023
Not Yet Recruiting
10
Xiangyang Central Hospital
Xiangyang, Hubei, China, 441138
Not Yet Recruiting
11
The First People's Hospital of Changde City
Changde, Hunan, China, 415000
Not Yet Recruiting
12
Jiangsu Province Hospital（The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital)
Nanjing, Jiangsu, China, 210029
Not Yet Recruiting
13
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Not Yet Recruiting
14
Affiliated Zhongshan Hospital Dalian University
Dalian, Liaoning, China, 116001
Not Yet Recruiting
15
Liaoning cancer hospital &institute
Shenyang, Liaoning, China, 110042
Not Yet Recruiting
16
Affiliated Zhongshan Hospital Dalian University
Jinan, Shandong, China, 250117
Not Yet Recruiting
17
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 201321
Actively Recruiting
18
Shanxi Cancer Hospital
Taiyuan, Shanxi, China, 30013
Not Yet Recruiting
19
Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital
Sichuan, Sichuan, China, 610072
Not Yet Recruiting
20
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China, 300300
Not Yet Recruiting
Research Team
N
Ning Wang, MM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here